A new blood test for diagnosing Alzheimer’s disease is on the horizon, potentially replacing more invasive and costly methods like spinal taps and brain scans. This test could make diagnosis faster, more accessible, and cheaper, allowing more people to start treatment at earlier stages of the disease. Current diagnostic methods include PET scans and cerebral spinal fluid analysis, both of which have limitations. A highly accurate blood test, such as the APS2 test developed by Lund University, could revolutionize the diagnosis process, improve access to care, and lead to earlier intervention for the millions of Americans with Alzheimer’s or mild cognitive impairment.
Source link
How a simple blood test could affect how Alzheimer’s is diagnosed
